|+1 404 474 4654|
|+1 888 205 9894 (TF)|
C-Abl Oncogene 1, Non-Receptor tyrosine Kinase (ABL1) (pTyr272) antibody
|Synonyms||ABL, JTK7, p150, c-ABL, v-abl, bcr/abl, Abl, c-Abl, AI325092, MGC117749, E430008G22Rik, ABL1, ARG, ABLL, FLJ22224, FLJ31718, FLJ41441, Arg, Abll, AA536808, MGC169395, ABL2, CABL, cb272|
Alternatives Immunohistochemistry (IHC), Dot Blot (Dot), ELISA
|5 references available|
|Quantity||400 µL (0.25 mg/ml)|
|Price||280.50 $ Plus shipping costs $45.00|
|Availability||Will be delivered in 2 to 3 Business Days|
|Immunogen||This Phospho-ABL1-Y272 antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding Y272 of human ABL1.|
|Description||Other names: Proto-oncogene tyrosine-protein kinase ABL1, p150, c-ABL, Abelson murine leukemia viral oncogene homolog 1, ABL1, ABL, JTK7,|
|Characteristics||Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)|
|Specificity||This Phospho-ABL1-Y272 antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding Y272 of human ABL1.|
|Molecular Weight||122873 DA|
Background: ABL1 is a cytoplasmic and nuclear protein tyrosine kinase that has been implicated in processes of cell differentiation, cell division, cell adhesion, and stress response. Activity of c-Abl protein is negatively regulated by its SH3 domain, and deletion of the SH3 domain turns ABL1 into an oncogene. The t(9,22) translocation results in the head-to-tail fusion of the BCR and ABL1 genes present in many cases of chronic myelogeneous leukemia. The DNA-binding activity of the ubiquitously expressed ABL1 tyrosine kinase is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function for ABL1.
|Application Notes||The suggested dilution is: ELISA~~1:1,000 Immunohistochemistry~~1:50~100 Dot Blot 1:500|
|Buffer||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is first purified by protein G affinity chromatography. Then, the antibody fraction is peptide affinity purified in a 2-step procedure with control and phosphorylate|
|Storage||Maintain refrigerated at 2-8 deg C for up to 6 months. For long term storage store at -20 deg C in small aliquots to prevent freeze-thaw cycles|
|Research Area||Apoptosis/Necrosis, Phospho-specific antibodies, Cell Signaling, Protein Modifications, Cancer, Cell Cycle, Cell Structure|
|Restrictions||For Research Use only|
Aichberger, Mayerhofer, Krauth et al.: "Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides." in: Blood, Vol. 105, Issue 8, pp. 3303-11, 2005 (PubMed).
Wei, Li, Liu: "Insights into selective activation of p53 DNA binding by c-Abl." in: The Journal of biological chemistry, Vol. 280, Issue 13, pp. 12271-8, 2005 (PubMed).
Robinson, Martineau, Harris et al.: "Derivative chromosome 9 deletions are a significant feature of childhood Philadelphia chromosome positive acute lymphoblastic leukaemia." in: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, Vol. 19, Issue 4, pp. 564-71, 2005 (PubMed).
Kim, Cho, Yoon et al.: "Interpretation of submicroscopic deletions of the BCR or ABL gene should not depend on extra signal-FISH: problems in interpretation of submicroscopic deletion of the BCR or ABL gene with extra signal-FISH." in: Genes, chromosomes & cancer, Vol. 43, Issue 1, pp. 37-44, 2005 (PubMed).
Barnes, McIntosh, Whetton et al.: "Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation." in: Oncogene, Vol. 24, Issue 20, pp. 3257-67, 2005 (PubMed).